Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.

Authors :: Kikuchi T
Tsukada N
Kunisada K
Matsumoto C
Nomura-Yogo M
Oda Y
Sato K
Takei T
Ogura M
Abe Y
Suzuki K
Hosoya O
Ishida T
Source :: Annals of hematology [Ann Hematol] 2024 Sep; Vol. 103 (9), pp. 3811-3813. Date of Electronic Publication: 2024 Jun 06.
Publication Year :: 2024

Subjects :: Humans
Female
Male
Aged
Middle Aged
Prognosis
Treatment Outcome
Retrospective Studies
Aged, 80 and over
Chromosome Aberrations
Lenalidomide therapeutic use
Lenalidomide administration & dosage
Multiple Myeloma drug therapy
Multiple Myeloma diagnosis
Dexamethasone administration & dosage
Dexamethasone therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal administration & dosage

Full Text Access

Tools